- Find our latest Case Studies
- Our Platforms
Platform 4: Advanced AMR Modelling
This platform in molecular pharmacology and pharmacokinetics-pharmacodynamics (PK-PD) led by the University of Liverpool provides new drug development models and approaches to help industry develop new agents to meet the challenge of antimicrobial resistance. It supports the discovery and development of novel therapeutics to tackle the world’s most critical, multi-drug-resistant infections.
The multi-drug-resistant pathogens Pseudomonas aeruginosa and Acinetobacter baumannii are key threats to human health at a global scale. New drugs are urgently required, however robust tools to assess these compounds at the early therapeutic lead stage are poorly developed.
To support industrial innovation, we are extending a suite of model systems that enable new therapeutic solutions for Pseudomonas aeruginosa and Acinetobacter baumannii. These include new experimental model systems of hospital acquired pneumonia, which continues to be associated with unacceptably high mortality and developing engineered strains that display a variety of resistance mechanisms while remaining highly pathogenic.
For more information or to learn how your business can engage with this platform.
Platform Lead
Professor William Hope OBE (FRACP, FRCPA, PhD)
Dame Sally Davies Chair of AMR Research – Director, Centre of Excellence in Infectious Diseases Research University of Liverpool
Professor William Hope OBE (FRACP, FRCPA, PhD)
Dame Sally Davies Chair of AMR Research – Director, Centre of Excellence in Infectious Diseases Research University of Liverpool
Dame Sally Davies Chair of AMR Research – Director, Centre of Excellence in Infectious Diseases Research – Co-Lead, NIHR Infectious Diseases National Specialty Group University of Liverpool.
Professor Hope qualified in Medicine in 1991, before undertaking specialist training in infectious diseases and clinical microbiology. He completed his PhD in antimicrobial pharmacology in 2006, while undertaking fellowships at the University of Manchester, UK, and the National Institutes of Health, Bethesda, USA. He was an NIHR Clinician Scientist and this award focussed on individualised antimicrobial therapy.
Professor Hope leads the Centre of Excellence in Infectious Diseases Research (CEIDR) which focuses on infection therapeutics. Areas of special interest and research are antimicrobial pharmacokinetics and pharmacodynamics, antimicrobial drug development and individualisation of antimicrobial therapy. He is a Fellow of the American Academy of Microbiology and European Society of Clinical Microbiology and Infectious Diseases as well as NIHR National Specialty Co-Lead for Infectious Diseases. Professor Hope is a Fellow of the Royal Australasian College of Physicians and a Fellow of the Royal College of Pathologists of Australasia and is the National Institute of Health Research Clinical Research Network Co-lead for Infectious Diseases.
